Method to correlate 1H MRSI and 18FDG-PET

Magnetic Resonance in Medicine

Volumn 43, Issue 2, 2000, Pages 244-250

  O'Neill, Joseph ^a,b   Eberling, Jamie Lynn ^c,d   Schuff, Norbert ^a,b   Jagust, William ^c,d   Reed, Bruce ^c,d   Soto, Gabriel ^a,b   Ezekiel, Frank ^a,b   Klein, Gregory ^c,d   Weiner, Michael W ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CMRglc; FDG PET; NAA; Proton MRSI

Indexed keywords

BRAIN; METABOLISM; NEURONS; POPULATION STATISTICS;

CMRGLC; COGNITIVELY IMPAIRED; CONTROL SUBJECT; FDG PET; METABOLIC ACTIVITY; METABOLIC RATES; N-ACETYL ASPARTATE; POSITRON EMISSION TOMOGRAPHY (PET);

POSITRON EMISSION TOMOGRAPHY;

GLUCOSE; N ACETYLASPARTIC ACID; ASPARTIC ACID; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORODEOXYGLUCOSE F 18; N-ACETYLASPARTATE; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; BRAIN METABOLISM; CELL DENSITY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; ALGORITHM; ANALYSIS OF VARIANCE; BRAIN; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; INSTRUMENTATION; METABOLISM; METHODOLOGY; REFERENCE VALUE; STATISTICS;

AGED; ALGORITHMS; ANALYSIS OF VARIANCE; ASPARTIC ACID; BRAIN; COGNITION DISORDERS; DEMENTIA; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; RADIOPHARMACEUTICALS; REFERENCE VALUES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033621634     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2594(200002)43:2<244::AID-MRM11>3.0.CO;2-2     Document Type: Article

References (39)

1. Jagust WJ. Functional imaging in dementia: an overview. J Clin Psychiatry 1994;55(suppl):511.
2. Jagust WJ., Functional imaging patterns in Alzheimer's disease. Relationships to neurobiology. Ann NY Acad Sci 1996;777:30-36.
3. Jagust WJ, Budinger TF. New neuroimaging techniques for investigating of brain-behavior relationships. Nida Res Monogr 1992;124:95-115.
4. Magistretti JP, Pellerin L. Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders. Ann NY Acad Sci 1996;777:380-87.
5. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acertylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 1992; 59:55-61.
6. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981-989.
7. Kwan LT, Reed BF, Eberling JL, Jagust WJ, Schuff N, Tanabe J, Norman D, Weiner MW. Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function. Arch Neurol 1999;56:809-814.
8. Tanabe J, Amend D, Schuff N, DiSclafani V, Ezekiel F, Norman D, Fein G, Weiner MW. Tissue segmentation of the brain in Alzheimer's disease. Am J Neuroradiol 1997;18:115-123.
9. Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer JF, Mastrianni JA, Fein G, Weiner MW. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease: a proton MR spectroscopic imaging and MRI study. Neurology 1997;49: 1513-1521.
10. 1H MR spectroscopic imaging. Radiology 1996;198:537-545.
11. Rooney WD, Miller RG, Gelinas D, Schuff N, Maudsley AA, Weiner MW. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 1998;50:1800-1805.
12. 1H spectroscopic imaging by data extrapolation. Magn Reson Med 1996; 35:678-687.
13. Soher BJ, Young K, Govindaraju V, Maudsley AA. Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med 1998;40:822-831.
14. 1H magnetic resonance spectroscopic imaging. Arch Neurol 1996; 53:167-174.
15. Müller-Gärtner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12: 571-583.
16. Jagust W, Eberling JL, Richardson BC, Reed BR, Baker MG, Nordahl TE, Budinger TF. The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease. Brain Res 1993;629:189-198.
17. Phelps ME, Huang SC, Hoffmann EJ, Kuhl DE. Validation of tomographic measurement of local cerebral glucose metabolic rate in human with (F-18)2-fluoro-2-deoxyglucose: validation of method. Ann Neurol 1979;6:371-388.
18. Labbé C, Froment JC, Kennedy A, Ashburner J, Cinotti L. Positron emission tomography metabolic data corrected for cortical atrophy using magnetic resonance imaging. Alzheimer Dis Assoc Disord 1996; 10:141-170.
19. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss W-D. The ECAT EXACT HR: Performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994;18: 110-118.
20. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992;16: 620-633.
21. Alger JR, Frank JA, Bizzi A, Fulham MJ, DeSouza BX, Duhaney MO, Inscoe SW, Black JL, van Zijl PCM, Moonen CTW, Di Chiro G. Metabolism of human gliomas: assessment with H-1 spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990;177:633-641.
22. Anderson JH, Strandberg JD, Wong DF, Conti PS, Barker PB, Blackband SJ, Hilton J, Natarajan TK, Dannals RF, Samphilipo MA, Magee CA, Burckhardt DD. Multimodality correlative study of canine brain tumors: proton magnetic resonance spectroscopy, positron emission tomography, and histology. Invest Radiol 1994;29:597-605.
23. 18F-fluorodeoxyglucose positron emission tomography. Magn Reson Med 1997;37:18-23.
24. Luyten PR, Marien AJH, Heindel W, van Gerwen PHJ, Herholz K, den Hollander JA, Friedmann G, Heiss W-D. Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 1990;176:791-799.
25. Preul MC, LeBlanc R, Cendes F, Dubeau F, Reutens D, Spreafico R, Battaglia G, Avoli M, Langevin P, Arnold DL, Villemure JG. Function and organization in dysgenic cortex. Case report. J Neurosurg 1997;87: 113-121.
26. Duncan DB, Herholz K, Kugel H, Roth B, Ruitenbeek W, Heindel W, Wienhard K, Heiss W-D. Positron emission tomography and magnetic resonance spectroscopy of cerebral glycolysis in children with congenital lactic acidosis. Ann Neurol 1995;37:351-358.
27. 1H-magnetic resonance spectroscopy. Stereotact Funct Neurosurg 1996;66(suppl 1):240-259.
28. 1H spectroscopic imaging of human brain at 4.1 T using image segmentation. Magn Reson Med 1996;36:21-29.
29. Hetherington HP, Mason GF, Pan JW, Ponder SL, Vaughan JT, Twieg DB, Pohost GM. Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1 T. Magn Reson Med 1994;32:565-571.
30. Lim KO, Spielman DM. Estimating NAA in cortical gray matter with applications for measuring changes due to aging. Magn Reson Med 1997;37:372-377.
31. Duara R. Utilization of positron emission tomography for research and clinical applications. In: Duara R, editor. Positron emission tomography in dementia. New York: Wiley-Liss; 1990. p 1-12.
32. Duara R, Loewenstein DA, Barker WW. Utilization of behavioral activation paradigms for positron emission tomography studies in normal young and elderly subjects and in dementia. In: Duara R, editor. Positron emission tomography in dementia. New York: Wiley-Liss; 1990. p 1311-148.
33. Horwitz B. Quantification and analysis of positron emission tomography metabolic data. In: Duara R, editor. Positron emission tomography in dementia. New York: Wiley-Liss; 1990. p 13-70.
34. Chawluk JB, Fazekas F, Alavi A, Dann R, Bais S, Reivich M. Effect of cerebral atrophy in positron emission tomography studies of aging and dementia. In: Duara R, editor. Positron emission tomography in dementia. New York: Wiley-Liss; 1990. p 71-92.
35. Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998;9:1757-1761.
36. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994;32:110-115.
37. Sultzer DL, Mahler ME, Cummings JL, Van Gorp WG, Hinkin CH, Brown C. Cortical abnormalities associated with subcortical lesions in vascular dementia. Arch Neurol 1995;52:773-780.
38. Jagust WJ, Haan MN, Eberling JL, Wolfe N, Reed BR. Functional imaging predicts cognitive decline in Alzheimer's disease. J Neuroimaging 1996;6:156-160.
39. Schuff N, Amend DL, Meyerhoff DJ, Tanabe JL, Norman D, Fein G, Weiner MW. Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology 1998;207:91-102.